- Home
- UHT vs AQST Comparison
UHT vs AQST Comparison
Compare UHT & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UHT | AQST |
|---|---|---|
| Founded | 1986 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 561.5M | 529.4M |
| IPO Year | 1995 | 2007 |
Fundamental Metrics
Financial Performance| Metric | UHT | AQST |
|---|---|---|
| Price | $38.56 | $4.69 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $43.00 | $9.00 |
| AVG Volume (30 Days) | 82.8K | ★ 2.3M |
| Earning Date | 04-27-2026 | 05-01-2026 |
| Dividend Yield | ★ 7.33% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.79 | N/A |
| Revenue | ★ $99,190,000.00 | $67,430,000.00 |
| Revenue This Year | $2.12 | $10.08 |
| Revenue Next Year | $2.94 | $49.60 |
| P/E Ratio | $48.96 | ★ N/A |
| Revenue Growth | 0.18 | ★ 0.77 |
| 52 Week Low | $35.26 | $2.94 |
| 52 Week High | $46.30 | $7.55 |
Technical Indicators
Market Signals| Indicator | UHT | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 32.06 | 47.56 |
| Support Level | $38.11 | $4.51 |
| Resistance Level | $40.90 | $5.10 |
| Average True Range (ATR) | 0.77 | 0.26 |
| MACD | -0.20 | -0.06 |
| Stochastic Oscillator | 10.94 | 20.41 |
Price Performance
Historical ComparisonAbout UHT Universal Health Realty Income Trust
Universal Health Realty Income Trust is a healthcare REIT. The company is engaged in the business of investing in and leasing healthcare and human service facilities through direct ownership or through joint ventures, which aggregate into a single reportable segment. The company actively manages a portfolio of healthcare and human service facilities. The revenue and net income are generated from the operation of the investment portfolio, located throughout the United States.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.